Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer

被引:41
|
作者
Asuthkar, Swapna [1 ]
Stepanova, Victoria [4 ]
Lebedeva, Tatiana [4 ]
Holterman, AiXuan L. [2 ]
Estes, Norman [2 ]
Cines, Douglas B. [4 ]
Rao, Jasti S. [1 ]
Gondi, Christopher S. [3 ]
机构
[1] Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA
[2] Univ Illinois, Coll Med Peoria, Dept Surg, Peoria, IL 61605 USA
[3] Univ Illinois, Coll Med Peoria, Dept Med, Peoria, IL 61605 USA
[4] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-STROMAL INTERACTIONS; GLIOMA-CELL INVASION; DOWN-REGULATION; RECEPTOR UPAR; SIDE POPULATION; ANTISENSE UPAR; HAIRPIN RNA; EXPRESSION; GROWTH;
D O I
10.1091/mbc.E12-04-0306
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is almost always lethal. One of the underlying reasons for this lethality is believed to be the presence of cancer stem cells (CSC), which impart chemoresistance and promote recurrence, but the mechanisms responsible are unclear. Recently the poor prognosis of PDAC has been correlated with increased expression of urokinase plasminogen activator (uPA). In the present study we examine the role of uPA in the generation of PDAC CSC. We observe a subset of cells identifiable as a side population (SP) when sorted by flow cytometry of MIA PaCa-2 and PANC-1 pancreatic cancer cells that possess the properties of CSC. A large fraction of these SP cells are CD44 and CD24 positive, are gemcitabine resistant, possess sphere-forming ability, and exhibit increased tumorigenicity, known characteristics of cancer stemness. Increased tumorigenicity and gemcitabine resistance decrease after suppression of uPA. We observe that uPA interacts directly with transcription factors LIM homeobox-2 (Lhx2), homeobox transcription factor A5 (HOXA5), and Hey to possibly promote cancer stemness. uPA regulates Lhx2 expression by suppressing expression of miR-124 and p53 expression by repressing its promoter by inactivating HOXA5. These results demonstrate that regulation of gene transcription by uPA contributes to cancer stemness and clinical lethality.
引用
收藏
页码:2620 / 2632
页数:13
相关论文
共 50 条
  • [41] Amiloride Analogues as Inhibitors of Human Urokinase Plasminogen Activator and Anti-Pancreatic Cancer Agents
    Xu, Z.
    Buckley, B. J.
    Pothula, S.
    Pang, T.
    Goldstein, D.
    Pirola, R. C.
    Wilson, J. S.
    Kelso, M. J.
    Ranson, M.
    Apte, M. V.
    PANCREAS, 2018, 47 (10) : 1434 - 1434
  • [42] The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC)
    Janisch, Florian
    D'Andrea, David
    Iwata, Takehiro
    Kimura, Shoji
    Abufaraj, Mohammad
    Enikeev, Dmitry
    Glybochko, Petr V.
    Karakiewicz, Pierre I.
    Nyirady, Peter
    Fajkovic, Harun
    Haitel, Andrea
    Seebacher, Veronika
    Rink, Michael
    Shariat, Shahrokh F.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (05) : 423 - 432
  • [43] Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA)
    Rabbani, SA
    Harakidas, P
    Davidson, DJ
    Henkin, J
    Mazar, AP
    INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (06) : 840 - 845
  • [44] Green tea polypheniols modulate secretion of urokinase plasminogen activator (uPA) and inhibit invasive behavior of breast cancer cells
    Slivova, V
    Zaloga, G
    DeMichele, SJ
    Mukerji, P
    Huang, YS
    Siddiqui, R
    Harvey, K
    Valachovicova, T
    Sliva, D
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2005, 52 (01): : 66 - 73
  • [45] CORRELATION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (UPA) WITH SURVIVAL IN DUKES-B COLORECTAL-CANCER
    MULCAHY, H
    GIBBONS, D
    MCCARTHY, P
    DUFFY, MJ
    PARFREY, NA
    SHEAHAN, K
    ODONOGHUE, DP
    GASTROENTEROLOGY, 1994, 106 (04) : A417 - A417
  • [46] Pectin inhibits invasiveness of breast and prostate cancer cells by down-regulation of urokinase plasminogen activator (uPA) secretion
    Wojnowski, Rachael
    Jiang, Jiahua
    Jedinak, Andrej
    Sliva, Daniel
    FASEB JOURNAL, 2010, 24
  • [47] Circulating plasma levels of the urokinase plasminogen activator (uPA), and its receptor (uPAR), in controls and patients with lung cancer.
    Cobos, E
    Jumper, C
    Cruz, J
    Hardwicke, F
    Lox, C
    BLOOD, 2001, 98 (11) : 69B - 69B
  • [48] CLINICAL-SIGNIFICANCE OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (UPA) IN INVASIVE CERVICAL-CANCER OF THE UTERUS
    SUGIMURA, M
    KOBAYASHI, H
    KANAYAMA, N
    TERAO, T
    GYNECOLOGIC ONCOLOGY, 1992, 46 (03) : 330 - 336
  • [49] Urokinase type plasminogen activator (UPA) and cathepsin B (CATB) plasma levels in gastro-intestinal tract cancer
    Farinati, F
    Foschia, F
    Cardin, R
    Plebani, M
    De Paoli, M
    Gianni, S
    Rinaldi, M
    Naccarato, R
    GASTROENTEROLOGY, 1999, 116 (04) : A400 - A400
  • [50] Expression of Urokinase-type Plasminogen Activator (uPA), uPA Receptor, and Plasminogen Activator Inhibitor-1 in Oral Squamous Cell Carcinoma
    Inoue, Yoshiko
    Sugiura, Tsuyoshi
    VIatsuki, Ryousuke
    Ishii, Kotaro
    Seki, Katsuhiro
    Shirasuna, Kanemitsu
    ORAL SCIENCE INTERNATIONAL, 2007, 4 (01) : 38 - 44